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mean transit time (MTT) and standardized uptake value (SUV) 
were determined for the following structures: GTVPET, GTVPT, 
GTVLN, as well as 5 mm and 10 mm margins from GTVPT and 
GTVLN. The 10 mm margin corresponds to the PTV and 5 mm 
margin was added to the analysis to study the signal changes 
in the PTV periphery. Voxel-wise Spearman correlations of 
perfusion parameters (BV, BF, MTT) and SUV were studied for 
each patient and each volume. Mean correlation coefficients 
corresponding to each structure were calculated to examine 
the population correlation. Moreover, correlations of mean 
BV, BF and MTT with SUVmean and SUVmax were tested. 
Differences of median values of mean BV, BF and MTT for 
various volumes among the patients population were 
investigated using paired Wilcoxon test. The significance 
level chosen for correlation study was 0.05 and for Wilcoxon 
test 0.01. 
Results: Based on the voxel-wise study no population-based 
correlation between perfusion parameters and SUV was 
found. A significant correlation was observed between mean 
MTT and SUVmean in the GTVPET of the PT (p=0.05) with a 
correlation coefficient of r = 0.73 for T1/T2 tumors and of r = 
0.55 for T3/T4. For both PTVPT and PTVLN, significant 
correlations between mean BF and SUVmean were found with 
the same correlation coefficient r = 0.44. Such dependencies 
were not observed for GTVPT and GTVLN, but the similar 
correlation was found for alone 5 mm (r = 0.50) and 10 mm (r 
= 0.44) margins from GTVLN. A difference was found for 
median value of BV between GTV and its 5 mm margin for PT 
and LN for all patients. This difference was observed for 
GTVPT corresponding to stage T3/T4, but was not significant 
for stage T1/T2. The median MTT was found to be 
significantly higher in GTVPT in comparison to its 5 mm 
margin. 
Conclusions: Tumor and surrounding normal tissue exhibit 
differential CT perfusion parameters. Analysis of PET and CT 
perfusion showed a positive correlation for SUVmean and MTT 
for the GTVPET. Therefore increased tumor perfusion and 
glucose metabolism seem to be part of a specific tumor 
physiology. Further studies are needed to investigate if 
specific tumor physiology predicts for response or resistance 
to radiotherapy.  
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Purpose/Objective: Neo-adjuvant chemoradiotherapy (nCRT) 
followed by surgery has become the standard treatment with 
curative intent for esophageal cancer patients. Despite the 
improved overall survival compared to surgery alone, the 
patients' quality of life (QoL) remains low due to the high 
burden of esophagectomy and high incidence of post-
operative complications. QoL would be improved by 
postponing surgery and a wait-and-see policy for patients 
with a complete pathological response to nCRT. Therefore, 
we investigated the feasibility of FDG-PET/CT derived 
variables to predict this pathological response. 
Materials and Methods: Patients with histologically proven 
esophageal cancer (stage IIA – IIIC) that received a baseline 
PET/CT scan 1-4 weeks prior to the start of the nCRT were 
included. A pre-surgery PET/CT scan was made 5-7 weeks 
after the last radiation dose. Gross tumor volumes (GTVs) 
were delineated on the baseline diagnostic PET/CT scan or 
were copied from the radiotherapy planning CT scan. The 
volume of the GTV and the mean, maximum and peak 
standard uptake values (SUVmean, SUVmax, and SUVpeak, 
respectively) within the GTV were determined. The 
metabolic tumor volume (MTV) was defined as the region 
with a SUV > 40% of SUVmax, and SUVmeanMTV was the mean SUV 
within this volume. The total lesion glycolysis (TLG) was 
defined as MTV x SUVmeanMTV. Tumor response to nCRT was 
evaluated using the Mandard regression classification (TRG 1-
5) on the pathological specimen after surgery. Patients were 
divided in responders (TRG 1-2) and non-responders (TRG 3-5) 
for statistical analysis. 
Results: Imaging and clinical results of 25 patients treated 
since mid-2012 were available. In total 28% (N=7) patients 
showed a pathological complete response (TRG 1) at the 
primary tumor site, and 32% (N=8) patients had a TRG 2, 
these patients were identified as responders. All other 
patients (40%, N=10) had a higher TRG and were defined as 
non-responders.  
Looking only at the baseline or pre-surgery scan was not able 
to show a significant difference between both groups for any 
of the investigated variables. However, the relative changes 
between the two PET/CT scans were prognostic. Responders 
had a significantly higher reduction in SUVmax (-50±26 vs. -
16±41, P=0.017), SUV-peak (-52±27 vs. -19±40, P=0.021) and 
SUVmeanMTV (-51±30 vs. -18±43, P=0.031), also shown in figure 
1. Multivariate analysis and external validation is ongoing. 
 
Conclusions: The relative change in FDG-uptake at the 
primary tumor site before and after nCRT has a prognostic 
value for response assessment of esophageal cancer patients. 
Responders showed a significantly larger decrease in uptake 
than non-responders. The prediction of pathological response 
using two PET/CT scans could be a useful method for future 
treatment decisions.  
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